한빛사 논문
Abstract
Daishun Ling†‡, Hongping Xia§, Wooram Park⊥, Michael J. Hackett†‡, Changyeong Song†‡, Kun Na⊥, Kam Man Hui§*, and Taeghwan Hyeon†‡*
† Center for Nanoparticle Research, Institute for Basic Science (IBS), Seoul 151-742, Korea
‡ School of Chemical and Biological Engineering, Seoul National University, Seoul 151-742, Korea
§ Laboratory of Cancer Genomics, Division of Cellular and Molecular Research, Humphrey Oei Institute of Cancer Research, National Cancer Center Singapore, Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Institute of Molecular and Cell Biology, A*STAR, Biopolis Drive Proteos, Singapore 169610
⊥ Department of Biotechnology, The Catholic University of Korea, Bucheon-si, Gyeonggi-do 420-743, Korea
*Correspondence to Kam Man Hui, Taeghwan Hyeon
Abstract
Hepatocellular carcinoma (HCC) has one of the worst prognoses for survival as it is poorly responsive to both conventional chemotherapy and mechanism-directed therapy. This results from a lack of therapeutic concentration in the tumor tissue coupled with the highly toxic off-site effects exhibited by these compounds. Consequently, we believe the best packaging for holistic therapy for HCC will involve three components: a potent therapeutic, a rationally designed drug delivery vehicle to enrich the target site concentration of the drug, and a surface ligand that can enable a greater propensity to internalization by tumor cells compared to the parenchyma. We screened a library containing hundreds of compounds against a panel of HCC cells and found the natural product, triptolide, to be more effective than sorafenib, doxorubicin, and daunorubicin, which are the current standards of therapy. However, the potential clinical application of triptolide is limited due to its poor solubility and high toxicity. Consequently, we synthesized tumor pH-sensitive nanoformulated triptolide coated with folate for use in an HCC-subpopulation that overexpresses the folate receptor. Our results show triptolide itself can prevent disease progression, but at the cost of significant toxicity. Conversely, our pH-sensitive nanoformulated triptolide facilitates uptake into the tumor, and specifically tumor cells, leading to a further increase in efficacy while mitigating systemic toxicity.
Keywords: hepatocellular carcinoma; triptolide; pH sensitive polymer; targeted cancer therapy; drug delivery
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
관련분야 논문보기
해당논문 저자보기